TrialNature communications2026

Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis.

Wen Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.